Status:
UNKNOWN
AI-based Social Software to Manage wARfarin Therapy
Lead Sponsor:
Wuhan Asia Heart Hospital
Conditions:
Anticoagulant-induced Bleeding
Warfarin Sodium Causing Adverse Effects in Therapeutic Use
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The investigators have demonstrated that social software could improve warfarin therapy quality by Human management. however,the efficiency of management will decline if patients' number expands huge....
Detailed Description
1. The investigators have developed an AI-based miniprogram, and embedded in the Wechat social application. 2. The investigators invited patients receiving warfarin therapy to participant this randomi...
Eligibility Criteria
Inclusion
- Patients with Atrial fibrillation
- Patients with Mechanical valve replacement
- Patients receiving warfarin therapy
Exclusion
- Plan to stop warfarin therapy within 1 years
- Bleeding within 3 months
- Refuse to participate in this study
- Other conditions that the physician considers inappropriate for participation
Key Trial Info
Start Date :
May 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03870581
Start Date
May 1 2019
End Date
May 1 2021
Last Update
March 12 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
WAHH
Wuhan, Hubei, China, 430000
2
Wuhan Asia Heart Hospital
Wuhan, Hubei, China, 430022